## [Drug Approval Process in Brazil: 13 Must-Know FAQs Explained by ANVISA](/blog/drug-approval-process-in-brazil-13-must-know-faqs-explained-by-anvisa) February 29, 2024 ![Thirteen (13) Must-know FAQs on the Drug Approval Process in Brazil]() 2 min read - [Medicinal Products](/blog-main-categories/medicinal-products) - [Regulatory Affairs](/blog-main-categories/regulatory-affairs) Are you stepping into the world of pharmaceuticals in Brazil? Have you ever wondered how medicinal products or drugs are approved in the country? Understanding the **drug approval process in Brazil** is essential for companies planning to introduce medicines into this market. In this blog, we unveil **thirteen (13) must-know Frequently Asked Questions (FAQs) about ANVISA and drug registration in Brazil**, designed to help you understand the fundamentals of pharmaceutical approval in a clear and practical way. ### 1. What is ANVISA? The Agência Nacional de Vigilância Sanitária (**ANVISA**), or the National Health Surveillance Agency, is the Brazilian health regulatory authority responsible for evaluating whether medicines are **safe, effective, and compliant with regulatory standards** before they reach patients. In simple terms, ANVISA ensures that medicinal products marketed in Brazil meet quality and safety requirements. ### 2. Who is eligible to apply for new drug approval in Brazil? - Pharmaceutical companies legally established in Brazil and authorized to operate before the Brazilian Health Regulatory Agency (ANVISA). - Foreign pharmaceutical companies must submit applications through a Brazilian legal entity holding the appropriate regulatory authorization. ### 3. What kinds of drugs require approval in Brazil? - All new drugs, including prescription and over-the-counter (OTC) medicines - Biologics, such as vaccines and insulin - Generic drugs ### 4. What are the main steps involved in the drug approval process? - Pre-clinical studies to assess safety and efficacy - Clinical trials conducted in defined phases - Registration application submitted with a complete dossier to **ANVISA** - Technical evaluation by ANVISA experts - Approval or rejection based on regulatory review - Pricing approval by the Drug Market Regulation Chamber (CMED), when applicable, prior to commercialization in the Brazilian market. ### 5. How can you be sure a drug is safe to be placed on the Brazilian market? ANVISA follows **stringent scientific evaluation and international standards** before granting approval. Information on approved drugs and potential safety concerns is also available through ANVISA’s official communication channels. ### 6. Can drugs that are not approved in Brazil be imported?  Such situations may include specific regulatory pathways or exceptional cases such as importation for personal use under applicable regulatory requirements. ### 7. How can companies stay updated on new drug approvals in Brazil? You can stay informed by following **ANVISA’s official publications, newsletters, and digital platforms**. ### 8. Does ANVISA approve traditional medicines?  The regulatory framework for phytotherapeutic medicines has undergone updates in recent years as part of ANVISA’s ongoing modernization of medicinal product regulations. ### 9. Does ANVISA collaborate with other regulatory agencies? Yes. **ANVISA actively collaborates with international regulatory authorities**, promoting regulatory convergence and information exchange. ### 10. How does ANVISA ensure the quality of drugs manufactured in Brazil? ANVISA conducts **regular inspections of manufacturing facilities** and enforces strict quality control measures to ensure compliance with Good Manufacturing Practices (GMP). ### 11. What happens if a drug approved in Brazil later shows safety concerns? ANVISA continuously monitors medicines after approval and may issue warnings, restrict use, or **recall products if safety risks are identified**. ### 12. Is the approval process for OTC medicines different from prescription drugs?  In Brazil, OTC medicines are classified as **Medicamentos Isentos de Prescrição (MIP)** and must comply with the applicable regulatory framework defining the criteria and list of substances eligible for non-prescription status. ### 13. Are there plans to reform or modernize the drug approval process in Brazil? ANVISA continuously works to **modernize and improve its regulatory processes**, aligning with international best practices while maintaining high safety standards. Do you have questions about bringing your drug to the Brazilian market or navigating **ANVISA approval requirements**? **Our regulatory** [**experts**](javascript:void(0)) **can support you throughout the drug approval process in Brazil and help you move forward with confidence.**